Biomind Labs Inc
NEO:BMND
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Biomind Labs Inc
NEO:BMND
|
CA |
|
Reliance Steel & Aluminum Co
NYSE:RS
|
US |
|
Harford Bank
OTC:HFBK
|
US |
|
D
|
DT Cloud Star Acquisition Corp
NASDAQ:DTSQ
|
US |
|
A
|
Acom Co Ltd
F:AK5
|
JP |
|
I
|
ITX AI Co Ltd
KOSDAQ:099520
|
KR |
|
Identillect Technologies Corp
XTSX:ID
|
CA |
|
Twelve Seas Investment Company III
NASDAQ:TWLV
|
US |
Biomind Labs Inc
Biomind Labs, Inc. operates as a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-07-27. The firm is primary engaged as a biotech platform, which integrates biology, chemistry, medicine, neuroscience, technology, intellectual property and pharma grade production. Through its platform, the Company is engaged in the development of pharmaceutical formulations of the main psychedelic molecules, DMT, 5-MeO-DMT (2-(5-Methoxy-1H-indol-3-yl)-N, N-dimethyltryptamine) and mescaline 2-(3,4,5-trimethoxyphenyl)-ethylamine for treating a range of therapeutic indications. 5-MeO-DMT is a psychotropicbiomolecule from the tryptamine class. 5-MeO-DMT is a potent agonist on 5-HT1A and 5-HT2A receptors. Ayahuasca is a psychoactive beverage that contains, as active ingredients, a complex mixture of alkaloids composed mainly by DMT and the β-carbolines harmine, harmaline and tetrahydroharmine. Mescaline is a phenylethylamine alkaloid structurally related to the neurotransmitter dopamine.
Biomind Labs, Inc. operates as a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-07-27. The firm is primary engaged as a biotech platform, which integrates biology, chemistry, medicine, neuroscience, technology, intellectual property and pharma grade production. Through its platform, the Company is engaged in the development of pharmaceutical formulations of the main psychedelic molecules, DMT, 5-MeO-DMT (2-(5-Methoxy-1H-indol-3-yl)-N, N-dimethyltryptamine) and mescaline 2-(3,4,5-trimethoxyphenyl)-ethylamine for treating a range of therapeutic indications. 5-MeO-DMT is a psychotropicbiomolecule from the tryptamine class. 5-MeO-DMT is a potent agonist on 5-HT1A and 5-HT2A receptors. Ayahuasca is a psychoactive beverage that contains, as active ingredients, a complex mixture of alkaloids composed mainly by DMT and the β-carbolines harmine, harmaline and tetrahydroharmine. Mescaline is a phenylethylamine alkaloid structurally related to the neurotransmitter dopamine.
